Moffitt Study Reveals Novel Mechanism Behind Immunotherapy Resistance

In a groundbreaking international collaboration, researchers from Moffitt Cancer Center, the Karolinska Institutet, and the University of Texas MD Anderson Cancer Center have uncovered an unexpected mechanism behind cancer’s resistance to immunotherapy. This novel insight reveals that certain tumors can actively injure adjacent nerves, triggering a cascade of inflammatory processes that ultimately diminish the effectiveness of anti-PD-1 treatments, commonly used immune checkpoint inhibitors in oncology. This discovery not only broadens our understanding of tumor biology but also suggests new therapeutic angles to counteract immune resistance.

The study, recently published in the prestigious journal Nature, provides robust evidence that the interaction between cancer cells and tumor-associated nerves plays a significant role in shaping the tumor microenvironment. Specifically, the cancerous cells infiltrate and degrade the protective myelin sheath surrounding these nerves. Damage to the nerve fibers leads to the release of inflammatory mediators such as interleukin-6 (IL-6) and type 1 interferons, which initially may trigger tissue repair mechanisms but eventually contribute to creating an immunosuppressive milieu that blunts anti-tumor immune responses.

Anti-PD-1 immunotherapy, which has revolutionized treatment for several cancers by unleashing T-cell mediated immune attack on malignant cells, faces a significant clinical challenge: many patients do not respond or develop resistance over time. The findings of this study shine a light on a previously unappreciated resistance pathway—nerve injury-induced inflammation—that actively suppresses immune activity within the tumor. By altering nerve integrity, tumors can effectively modulate immune surveillance and escape eradication.

Kenneth Tsai, M.D., Ph.D., co-corresponding author and co-director of the Donald A. Adam Melanoma and Skin Cancer Center of Excellence at Moffitt Cancer Center, stated that their team’s findings emphasize the direct influence of nerve injury on immune cell behavior within tumors. “Our research illustrates that nerve injury is not simply collateral damage from tumor growth, but rather a functional driver that remodels the immune landscape, facilitating immune evasion. The exciting part of our work is demonstrating that this process is reversible, opening the door to potential interventions,” Dr. Tsai explained.

Utilizing patient-derived samples and preclinical models encompassing a variety of cancer types—including cutaneous squamous cell carcinoma, melanoma, gastric cancer, and pancreatic cancer—the research team dissected the cellular dynamics at play. They observed that nerve damage induced by cancer cells triggers a complex inflammatory response, which, although initially reparative, transitions into a chronic suppressive state that dampens immune cell infiltration and activation.

To intervene in this detrimental feedback loop, the researchers explored multiple therapeutic strategies designed to restore immune sensitivity. They discovered that resistance to anti-PD-1 therapy could be mitigated by either surgically removing pain-transmitting nerves, pharmacologically blocking neuronal injury signaling pathways, or employing combination therapies that target both the PD-1 axis and the IL-6-mediated inflammatory pathways. These approaches successfully reversed tumor-induced immune resistance in preclinical settings, underscoring their translational potential.

This research highlights a critical and previously underexplored role for the nervous system in cancer progression and therapeutic resistance. Traditionally, oncology has focused primarily on the direct interactions between cancer cells and immune cells, but this study underscores that nerve-cancer cross talk can profoundly shape immunological outcomes. Targeting nerve injury-related signals could, therefore, become an innovative strategy to enhance responses to current immunotherapies.

Moreover, the study lays groundwork for future investigations into the molecular mechanisms by which nerve damage alters immune signaling within the tumor microenvironment. Key inflammatory mediators like IL-6 and type 1 interferons may become biomarkers for identifying patients likely to exhibit resistance due to nerve involvement. This stratification could guide personalized treatment regimens incorporating nerve-targeted therapies.

Clinically, targeting nerve injury pathways has compelling implications, especially for cancers characterized by perineural invasion—a phenomenon where tumors grow along nerves, commonly linked to poor prognosis and reduced treatment efficacy. By neutralizing the immune-suppressive signaling that arises from nerve damage, oncologists may improve therapeutic outcomes and extend patient survival.

Dr. Tsai further emphasized, “Understanding the bidirectional crosstalk between nerves and cancer cells reveals new vulnerabilities we can exploit therapeutically. Our discovery encourages an integrative perspective that combines neural biology and immunology to combat tumor immune evasion.”

The study was rigorously funded by the National Institutes of Health, underscoring its significance and potential impact on cancer research and treatment paradigms. As nerve-targeted therapy development advances, combination treatments involving immune checkpoint inhibitors and nerve injury signaling blockers could enter clinical trials, offering hope to patients who currently face limited options due to immune resistance.

In conclusion, this pioneering work broadens the conceptual framework of tumor immunology by incorporating the nervous system as a key player in cancer progression and resistance mechanisms. It challenges existing paradigms and paves the way for innovative, multi-modal treatment strategies that could transform patient outcomes in the era of precision oncology.

News Publication Date: 20-Aug-2025

Web References:
https://www.nature.com/articles/s41586-025-09370-8

References:
Tsai, K., et al. (2025). Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature. DOI: 10.1038/s41586-025-09370-8